Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) have been assigned a consensus rating of “Buy” from the twenty-six analysts that are presently covering the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $131.71.
Several equities research analysts have weighed in on the company. Jefferies Group reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Sunday, May 22nd. SunTrust Banks Inc. assumed coverage on Zimmer Biomet Holdings in a research report on Thursday, August 11th. They set a “buy” rating and a $155.00 price target on the stock. Argus raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $140.00 price target on the stock in a research report on Wednesday, May 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $143.00 price target (up from $134.00) on shares of Zimmer Biomet Holdings in a research report on Monday, July 18th. Finally, Morgan Stanley reissued a “buy” rating on shares of Zimmer Biomet Holdings in a research note on Wednesday, June 8th.
In related news, insider Daniel E. Williamson sold 2,716 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $129.96, for a total value of $352,971.36. Following the completion of the sale, the insider now owns 2,000 shares in the company, valued at approximately $259,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel P. Florin sold 15,000 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $124.98, for a total transaction of $1,874,700.00. Following the completion of the sale, the chief financial officer now owns 16,983 shares of the company’s stock, valued at approximately $2,122,535.34. The disclosure for this sale can be found here. 1.22% of the stock is currently owned by corporate insiders.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/zimmer-biomet-holdings-inc-nysezbh-receives-average-recommendation-of-buy-from-brokerages.html
Hedge funds have recently bought and sold shares of the stock. Zurich Insurance Group Ltd FI bought a new stake in Zimmer Biomet Holdings during the first quarter valued at $3,931,000. Legal & General Group Plc increased its stake in Zimmer Biomet Holdings by 14.2% in the first quarter. Legal & General Group Plc now owns 864,145 shares of the company’s stock valued at $92,143,000 after buying an additional 107,576 shares during the period. Eqis Capital Management Inc. increased its stake in Zimmer Biomet Holdings by 11.8% in the second quarter. Eqis Capital Management Inc. now owns 11,216 shares of the company’s stock valued at $1,350,000 after buying an additional 1,181 shares during the period. Renaissance Technologies LLC increased its stake in Zimmer Biomet Holdings by 84.4% in the first quarter. Renaissance Technologies LLC now owns 441,900 shares of the company’s stock valued at $47,120,000 after buying an additional 202,200 shares during the period. Finally, Clark Capital Management Group Inc. bought a new stake in Zimmer Biomet Holdings during the first quarter valued at $3,248,000. Hedge funds and other institutional investors own 88.42% of the company’s stock.
Shares of Zimmer Biomet Holdings (NYSE:ZBH) traded up 0.58% during midday trading on Thursday, reaching $124.13. The company’s stock had a trading volume of 431,209 shares. The company has a 50 day moving average price of $128.86 and a 200-day moving average price of $118.27. The stock has a market capitalization of $24.83 billion, a PE ratio of 113.36 and a beta of 0.95. Zimmer Biomet Holdings has a 52 week low of $88.27 and a 52 week high of $133.19.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, July 28th. The company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.97 by $0.05. The company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.90 billion. Zimmer Biomet Holdings had a return on equity of 16.12% and a net margin of 1.68%. The firm’s revenue for the quarter was up 65.6% compared to the same quarter last year. During the same period last year, the firm earned $1.58 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings will post $7.97 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 23rd will be issued a $0.24 dividend. The ex-dividend date is Wednesday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.78%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 157.38%.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.